Precision Biosciences (DTIL) Cash & Current Investments (2018 - 2025)
Precision Biosciences (DTIL) has disclosed Cash & Current Investments for 8 consecutive years, with $115.6 million as the latest value for Q4 2025.
- Quarterly Cash & Current Investments rose 33.92% to $115.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $115.6 million through Dec 2025, up 33.92% year-over-year, with the annual reading at $115.6 million for FY2025, 33.92% up from the prior year.
- Cash & Current Investments for Q4 2025 was $115.6 million at Precision Biosciences, up from $44.9 million in the prior quarter.
- The five-year high for Cash & Current Investments was $212.1 million in Q3 2022, with the low at $44.9 million in Q3 2025.
- Average Cash & Current Investments over 5 years is $132.9 million, with a median of $130.7 million recorded in 2024.
- The sharpest move saw Cash & Current Investments soared 59.98% in 2021, then tumbled 55.66% in 2025.
- Over 5 years, Cash & Current Investments stood at $143.7 million in 2021, then soared by 31.96% to $189.6 million in 2022, then tumbled by 38.45% to $116.7 million in 2023, then dropped by 26.03% to $86.3 million in 2024, then surged by 33.92% to $115.6 million in 2025.
- According to Business Quant data, Cash & Current Investments over the past three periods came in at $115.6 million, $44.9 million, and $62.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.